Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories

Page 2

Ambri absorbs $144m
The renewable energy battery developer, an MIT spinout, raised funding that will be used to expand its manufacturing capabilities.
PepGen unpacks $112.5m round
University of Oxford’s genetic therapeutics spinout has secured the crossover funding eight months after a series A round also backed by OSI.
Sonoma captures $265m in series B
Osage University Partners has backed the immunotherapy developer in a series B round, which took its overall funding to over $335m.
NuScale powers up with $152m
A range of strategic investors have backed a series A5 round for the clean nuclear energy technology developer that leverages OSU research.
Intervenn attracts $201m in series C
Intervenn Biosciences was co-founded by faculty members at Stanford University and University of California, Berkeley.
T-Knife secures $110m in series B
The MDC spinout raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.
Deep Genomics jumps into $180m series C
University of Toronto-linked Deep Genomics has picked up $180m in its series C round led by SoftBank Vision Fund 2.
Ring circles $117m series B
UPMC Enterprises has contributed to a $117m series B round for gene therapy developer Ring Therapeutics.
PsiQuantum crosses off $450m in funding
PsiQuantum has become the first unicorn in Imec.xpand’s portfolio as it fetched a valuation of more than $3bn.
Investors assist Artios in $153m series C
IP Group is among the investors backing the DDR cancer therapeutics developer’s latest round, which took its total funding to $320m.

test reg